{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T21:49:20Z","timestamp":1787694560314,"version":"build-2784847793"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2024J011355"],"award-info":[{"award-number":["2024J011355"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2022J011380"],"award-info":[{"award-number":["2022J011380"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-026-03682-7","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T10:46:37Z","timestamp":1777286797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["ABTB1 modulates EGFR signaling and confers icotinib sensitivity in lung adenocarcinoma"],"prefix":"10.1186","volume":"27","author":[{"given":"Si-Yang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen-hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-chun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Xun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Xing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Bian","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"2","key":"3682_CR1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","volume":"22","author":"F Zhou","year":"2025","unstructured":"Zhou F, Guo H, Xia Y, Le X, Tan DSW, Ramalingam SS, et al. The changing treatment landscape of EGFR-mutant non-small-cell lung cancer. Nat Rev Clin Oncol. 2025;22(2):95\u2013116.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"3682_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","volume":"2","author":"A Passaro","year":"2021","unstructured":"Passaro A, J\u00e4nne PA, Mok T, Peters S. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer. 2021;2(4):377\u201391.","journal-title":"Nat Cancer"},{"issue":"2","key":"3682_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers15020504","volume":"15","author":"Houssein Chhouri","year":"2023","unstructured":"Chhouri H, Alexandre D, Grumolato L. Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer. Cancers . 2023;15(2):504.","journal-title":"Cancers"},{"issue":"10","key":"3682_CR4","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S1470-2045(13)70355-3","volume":"14","author":"Y Shi","year":"2013","unstructured":"Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 2013;14(10):953\u201361.","journal-title":"Lancet Oncol"},{"issue":"3","key":"3682_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2217\/fon.14.249","volume":"11","author":"F Tan","year":"2015","unstructured":"Tan F, Shi Y, Wang Y, Ding L, Yuan X, Sun Y. Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer. Future Oncol. 2015;11(3):385\u2013397.","journal-title":"Future Oncol"},{"issue":"2","key":"3682_CR6","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/cas.14277","volume":"111","author":"L Lei","year":"2020","unstructured":"Lei L, Wang WX, Zhu YC, Li JL, Fang Y, Wang H, et al. Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study. Cancer Sci. 2020;111(2):679\u201386.","journal-title":"Cancer Sci"},{"issue":"1","key":"3682_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/cam4.2652","volume":"9","author":"L Lei","year":"2020","unstructured":"Lei L, Wang WX, Zhu YC, Li JL, Fang Y, Wang H, et al. Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study. Cancer Med. 2020;9(1):12\u20138.","journal-title":"Cancer Med"},{"key":"3682_CR8","doi-asserted-by":"publisher","first-page":"105583","DOI":"10.1016\/j.phrs.2021.105583","volume":"167","author":"RF Dong","year":"2021","unstructured":"Dong RF, Zhu ML, Liu MM, Xu YT, Yuan LL, Bian J, et al. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research. Pharmacol Res. 2021;167:105583.","journal-title":"Pharmacol Res"},{"issue":"6","key":"3682_CR9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccr.2005.05.007","volume":"7","author":"HW Lo","year":"2005","unstructured":"Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y, et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS\/NO pathway. Cancer Cell. 2005;7(6):575\u201389.","journal-title":"Cancer Cell"},{"issue":"1","key":"3682_CR10","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/s42003-021-02744-4","volume":"4","author":"T Ando","year":"2021","unstructured":"Ando T, Arang N, Wang Z, Costea DE, Feng X, Goto Y, et al. EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1. Commun Biology. 2021;4(1):1237.","journal-title":"Commun Biology"},{"issue":"23","key":"3682_CR11","doi-asserted-by":"publisher","first-page":"8288","DOI":"10.1158\/1078-0432.CCR-05-0827","volume":"11","author":"EB Haura","year":"2005","unstructured":"Haura EB, Zheng Z, Song L, Cantor A, Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res. 2005;11(23):8288\u201394.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3682_CR12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.molmed.2015.04.001","volume":"21","author":"K Shostak","year":"2015","unstructured":"Shostak K, Chariot A. EGFR and NF-\u03baB: partners in cancer. Trends Mol Med. 2015;21(6):385\u201393.","journal-title":"Trends Mol Med"},{"key":"3682_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cytogfr.2023.03.003","volume":"70","author":"Q He","year":"2023","unstructured":"He Q, Qu M, Bao H, Xu Y, Shen T, Tan D, et al. Multiple post-translational modifications ensure EGFR functionality: Potential therapeutic targets to overcome its drug-resistance mutations. Cytokine Growth Factor Rev. 2023;70:41\u201353.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"5","key":"3682_CR14","doi-asserted-by":"publisher","first-page":"C1313","DOI":"10.1152\/ajpcell.00494.2022","volume":"325","author":"W-L Liao","year":"2023","unstructured":"Liao W-L, Lin H, Li Y-H, Yang T-Y, Chen M-C. RAGE potentiates EGFR signaling and interferes with the anticancer effect of gefitinib on NSCLC cells. Am J Physiology-Cell Physiol. 2023;325(5):C1313\u201325.","journal-title":"Am J Physiology-Cell Physiol"},{"key":"3682_CR15","doi-asserted-by":"publisher","first-page":"101266","DOI":"10.1016\/j.drup.2025.101266","volume":"82","author":"Z Du","year":"2025","unstructured":"Du Z, Kan H, Sun J, Liu Y, Gu J, Akemujiang S, et al. Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resist Updates. 2025;82:101266.","journal-title":"Drug Resist Updates"},{"issue":"2","key":"3682_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2174\/0109298665254683231122065717","volume":"31","author":"Z Qin","year":"2024","unstructured":"Qin Z, Xu Y. Dexmedetomidine Alleviates Brain Ischemia\/Reperfusion Injury by Regulating Metastasis-associated Lung Adenocarcinoma Transcript 1\/MicroRNA-140-5p\/ Nuclear Factor Erythroid-derived 2-like 2 Axis. Protein Pept Lett. 2024;31(2):116\u201327.","journal-title":"Protein Pept Lett"},{"issue":"1","key":"3682_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2174\/0113892029277397231228062412","volume":"25","author":"M Li","year":"2024","unstructured":"Li M, Deng X, Zhou D, Liu X, Dai J, Liu Q. A Novel Methylation-based Model for Prognostic Prediction in Lung Adenocarcinoma. Curr Genomics. 2024;25(1):26\u201340.","journal-title":"Curr Genomics"},{"issue":"1","key":"3682_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2174\/0113892029298721240627095839","volume":"26","author":"Q Ren","year":"2025","unstructured":"Ren Q, Ma H, Wang L, Qin J, Tian M, Zhang W. Gene-knockdown Methods for Silencing Nuclear-localized Insulin Receptors in Lung Adenocarcinoma Cells: A Bioinformatics Approach. Curr Genomics. 2025;26(1):24\u201335.","journal-title":"Curr Genomics"},{"key":"3682_CR19","doi-asserted-by":"crossref","unstructured":"Zhu X, Zhang Y, Pan P, Liu X, Zhang J, Du X, et al. Identification and Validation of Amino Acid Metabolism-Related Biomarkers and Investigation of their Potential Mechanisms in Lung Adenocarcinoma. Curr Gene Ther. 2025;25.","DOI":"10.2174\/0115665232364091250203090710"},{"issue":"4","key":"3682_CR20","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nprot.2017.016","volume":"12","author":"J Joung","year":"2017","unstructured":"Joung J, Konermann S, Gootenberg JS, Abudayyeh OO, Platt RJ, Brigham MD, et al. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nat Protoc. 2017;12(4):828\u201363.","journal-title":"Nat Protoc"},{"issue":"W1","key":"3682_CR21","doi-asserted-by":"publisher","first-page":"W534","DOI":"10.1093\/nar\/gkaf388","volume":"53","author":"H Cui","year":"2025","unstructured":"Cui H, Zhao G, Lu Y, Zuo S, Duan D, Luo X, et al. TIMER3: an enhanced resource for tumor immune analysis. Nucleic Acids Res. 2025;53(W1):W534\u201341.","journal-title":"Nucleic Acids Res"},{"key":"3682_CR22","doi-asserted-by":"crossref","unstructured":"Bartha \u00c1, Gy\u0151rffy B. TNMplot.com: A Web Tool for the Comparison of Gene Expression in Normal, Tumor and Metastatic Tissues. Int J Mol Sci. 2021;22(5):2622.","DOI":"10.3390\/ijms22052622"},{"issue":"W1","key":"3682_CR23","doi-asserted-by":"publisher","first-page":"W283","DOI":"10.1093\/nar\/gkaf423","volume":"53","author":"YJ Kang","year":"2025","unstructured":"Kang YJ, Pan L, Liu Y, Rong Z, Liu J, Liu F. GEPIA3: Enhanced drug sensitivity and interaction network analysis for cancer research. Nucleic Acids Res. 2025;53(W1):W283\u201390.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"3682_CR24","first-page":"100625","volume":"5","author":"B Gy\u0151rffy","year":"2024","unstructured":"Gy\u0151rffy B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innov (Camb). 2024;5(3):100625.","journal-title":"Innov (Camb)"},{"issue":"5","key":"3682_CR25","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1002\/imt2.238","volume":"3","author":"D Chen","year":"2024","unstructured":"Chen D, Xu L, Xing H, Shen W, Song Z, Li H, et al. Sangerbox 2: Enhanced functionalities and update for a comprehensive clinical bioinformatics data analysis platform. Imeta. 2024;3(5):e238.","journal-title":"Imeta"},{"issue":"1","key":"3682_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/1471-2105-15-293","volume":"15","author":"P Bardou","year":"2014","unstructured":"Bardou P, Mariette J, Escudi\u00e9 F, Djemiel C, Klopp C. jvenn: an interactive Venn diagram viewer. BMC Bioinformatics. 2014;15(1):293.","journal-title":"BMC Bioinformatics"},{"issue":"5","key":"3682_CR27","doi-asserted-by":"publisher","first-page":"101065","DOI":"10.1016\/j.jpha.2024.101065","volume":"15","author":"O Menyhart","year":"2025","unstructured":"Menyhart O, Kothalawala WJ, Gy\u0151rffy B. A gene set enrichment analysis for cancer hallmarks. J Pharm Anal. 2025;15(5):101065.","journal-title":"J Pharm Anal"},{"key":"3682_CR28","doi-asserted-by":"crossref","unstructured":"Li K, Yang H, Lin A, Xie J, Wang H, Zhou J et al. CPADS: a web tool for comprehensive pancancer analysis of drug sensitivity. Brief Bioinform. 2024;25(3):bbae237.","DOI":"10.1093\/bib\/bbae237"},{"issue":"20","key":"3682_CR29","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1093\/bioinformatics\/btz210","volume":"35","author":"B Ru","year":"2019","unstructured":"Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC, et al. TISIDB: an integrated repository portal for tumor\u2013immune system interactions. Bioinformatics. 2019;35(20):4200\u20132.","journal-title":"Bioinformatics"},{"issue":"12","key":"3682_CR30","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1074\/mcp.M500279-MCP200","volume":"4","author":"M Uhl\u00e9n","year":"2005","unstructured":"Uhl\u00e9n M, Bj\u00f6rling E, Agaton C, Szigyarto CA, Amini B, Andersen E, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteom. 2005;4(12):1920\u201332.","journal-title":"Mol Cell Proteom"},{"issue":"1","key":"3682_CR31","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.","journal-title":"Nat Commun"},{"issue":"269","key":"3682_CR32","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.","journal-title":"Sci Signal"},{"issue":"1","key":"3682_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","volume":"25","author":"R Arafeh","year":"2025","unstructured":"Arafeh R, Shibue T, Dempster JM, Hahn WC, Vazquez F. The present and future of the Cancer Dependency Map. Nat Rev Cancer. 2025;25(1):59\u201373.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"3682_CR34","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman MJ, Craft B, Hastie M, Repe\u010dka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675\u20138.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"3682_CR35","doi-asserted-by":"publisher","first-page":"2574526","DOI":"10.1080\/07853890.2025.2574526","volume":"57","author":"J Wang","year":"2025","unstructured":"Wang J, Wang J, Chen J. Precision navigation through the labyrinth: overcoming EGFR resistance in non-Small cell lung cancer. Ann Med. 2025;57(1):2574526.","journal-title":"Ann Med"},{"issue":"18","key":"3682_CR36","doi-asserted-by":"publisher","first-page":"4986","DOI":"10.1158\/1078-0432.CCR-12-0792","volume":"18","author":"M Sen","year":"2012","unstructured":"Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, Maxwell J, et al. Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer. Clin Cancer Res. 2012;18(18):4986\u201396.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3682_CR37","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41419-021-03844-z","volume":"12","author":"Z Liu","year":"2021","unstructured":"Liu Z, Ma L, Sun Y, Yu W, Wang X. Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer. Cell Death Dis. 2021;12(6):561.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3682_CR38","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.celrep.2015.03.012","volume":"11","author":"CM Blakely","year":"2015","unstructured":"Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, et al. NF-\u03baB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep. 2015;11(1):98\u2013110.","journal-title":"Cell Rep"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03682-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03682-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03682-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:46:05Z","timestamp":1782179165000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03682-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3682"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03682-7","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not constitute human-subjects research; therefore, Institutional Review Board\u2019s review and informed consent were not required, consistent with applicable regulations and the Declaration of Helsinki. Clinical trial number: not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"251"}}